Compare SSTI & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SSTI | SPRO |
|---|---|---|
| Founded | 1996 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 84.8M | 73.4M |
| IPO Year | 2017 | 2017 |
| Metric | SSTI | SPRO |
|---|---|---|
| Price | $8.36 | $1.20 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 6 | 2 |
| Target Price | ★ $8.84 | $5.00 |
| AVG Volume (30 Days) | 219.4K | ★ 814.5K |
| Earning Date | 11-11-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 111.81 |
| EPS | N/A | ★ N/A |
| Revenue | $34,753,000.00 | ★ $66,802,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $9.42 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 46.25 | 39.24 |
| 52 Week Low | $5.42 | $1.08 |
| 52 Week High | $11.88 | $3.08 |
| Indicator | SSTI | SPRO |
|---|---|---|
| Relative Strength Index (RSI) | 70.17 | 49.50 |
| Support Level | $6.26 | $1.12 |
| Resistance Level | $8.68 | $1.28 |
| Average True Range (ATR) | 0.22 | 0.08 |
| MACD | 0.22 | 0.00 |
| Stochastic Oscillator | 86.78 | 22.58 |
SoundThinking Inc is a public safety technology company that combines transformative solutions and strategic advisory services for law enforcement and civic leadership. Its flagship SafetySmart platform includes: ShotSpotter, the acoustic gunshot detection system; CrimeTracer, the foremost law enforcement search engine; CaseBuilder, a one-stop investigation management system; ResourceRouter, software that directs patrol and community anti-violence resources to help maximize their impact; PlateRangerTM powered by Rekor, an automatic license plate recognition ("ALPR") and vehicle identification solution; SafePointe, an AI-based weapons detection system.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.